What is melatonin, and how the body uses it

When examining what is melatonin, the most essential biological distinction is that it operates as a chemical signal for darkness rather than a sedative. Melatonin is a hormone the body makes for itself, not a plant extract and not a sedative, chemically identified as 5-methoxy-N-acetyltryptamine. It is synthesised and released primarily by the pineal gland, a structure located near the centre of the brain, as well as locally in the retina. Production follows an innate circadian rhythm, maintaining low circulating concentrations during daytime hours and elevated levels throughout the night.

Endogenous production and the biological clock

The body builds melatonin from the essential amino acid tryptophan through intermediate conversion into serotonin. The critical rate-limiting rhythm is driven by an enzyme called arylalkylamine N-acetyltransferase, whose marked day-night fluctuation led researchers to term it the timezyme ^[4]. Because this enzymatic activity accelerates drastically after dusk, endogenous levels surge while you sleep and drop sharply as morning approaches.

The discovery of melatonin in 1958

Melatonin was isolated in 1958 by Aaron Lerner and colleagues at Yale from bovine pineal tissue. They named the substance for its ability to lighten pigment cells called melanocytes, without any initial focus on sleep ^[2]. Because the hormone was discovered through dermatology research rather than somnology, its name reflects cellular pigmentation rather than nighttime rest.

CIBDOL · The discovery of melatonin in 1958

Darkness as a physiological signal

What melatonin reports is darkness rather than tiredness, rising in the evening and falling before waking to provide an internal temporal cue. Because this nightly rise is consistent, sleep researchers use the onset of melatonin secretion in dim light as their reference marker for circadian phase position ^[3]. Physical activity and wakefulness do not alter the timing of this biological threshold.

Environmental illumination serves as the primary regulator. In a 1980 study, bright artificial light suppressed night-time melatonin secretion in six healthy human volunteers, whereas standard room light failed to suppress it. This experimental finding demonstrated that sufficient illumination abruptly halts nocturnal production ^[5].

Specific cellular receptors

Melatonin interacts directly with two dedicated high-affinity binding sites, named the MT1 and MT2 receptors, both of which are G protein-coupled receptors. These direct pathways differentiate it from compounds that act without dedicated targets ^[1]. By binding these receptors across the brain and peripheral organs, the hormone coordinates downstream physiological processes aligned with the nocturnal period.

Oral absorption and metabolic clearance

When taken orally, melatonin is absorbed and cleared rapidly from circulation. In a crossover trial involving 12 healthy male volunteers receiving oral and intravenous doses on separate days, oral plasma concentrations reached their peak at roughly 41 minutes, with an elimination half-life of approximately 54 minutes and a median oral bioavailability of around 3 percent due to extensive first-pass metabolism by the liver. These kinetic parameters explain why oral compounds act and clear within a relatively short window ^[6].

Because systemic clearance occurs rapidly, swallowed doses do not linger through the late hours of the night. Furthermore, circulating availability varies substantially between individuals based on hepatic metabolism.

What clinical trials have documented

A meta-analysis of 19 randomised placebo-controlled trials covering 1683 participants found that melatonin shortened sleep onset latency by an average of 7.06 minutes, with a 95 percent confidence interval of 4.37 to 9.75 minutes, and lengthened total sleep time by 8.25 minutes, with a 95 percent confidence interval of 1.74 to 14.75 minutes, with authors characterising the overall effects as modest. Furthermore, these measured differences did not diminish across extended treatment durations ^[7].

Evaluating this pooled evidence requires balancing both statistical significance and practical magnitude. A reduction in sleep onset latency of approximately seven minutes is measurable across large groups, but it represents an incremental physiological shift rather than profound sedation.

Regulatory status and product labelling

Under Regulation (EU) No 432/2012, exactly two health claims are authorised across the European Union for melatonin: one about the time taken to fall asleep and one about the subjective feelings of jet lag, and each may be used only under stated conditions.

Melatonin is not treated the same way in every country. In some European states it is sold as a food supplement, in others only as a medicine, and the permitted amount per daily dose differs between member states. The packaging of Cibdol Fall Asleep Liquid reflects these regional standards directly, listing distinct daily amounts for the Netherlands, Germany, and the remainder of the European Union.

Two Cibdol products declare melatonin on the label, Fall Asleep Liquid and Fall Asleep Capsules. Stay Asleep Capsules, Complete Sleep and CBN Oil do not contain it. This article describes published research and product labels. It does not give medical advice.